Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 7:42 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 539 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eruption Clear all
Completed Phase 3 Interventional

DMT310-009 Topical in the Treatment of Acne Vulgaris

NCT06090721
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
9 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Freemont, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Nov 2, 2026, 7:42 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis

NCT05942248
View directory record Official record
Conditions
Acne, Melasma, Rosacea, Seborrheic Dermatitis
Interventions
No Intervention
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Nov 2, 2026, 7:42 AM EST
Terminated Not applicable Interventional Results available

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 2, 2026, 7:42 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum

NCT04060550
View directory record Official record
Conditions
Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy
Interventions
Xolair
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
16 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

NCT00952523
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Facial Gel, Adapalene/Benzoyl Peroxide Facial Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

NCT03497897
View directory record Official record
Conditions
Inflammatory Acne
Interventions
LYS006 20 mg, LYS006 2 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Fremont, California • Santa Monica, California • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Nov 2, 2026, 7:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation

NCT07468175
View directory record Official record
Conditions
Hyperpigmentation, Dark Spots
Interventions
Cosmetic dark spot corrector serum
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 2 Interventional Results available

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 1 Interventional

A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris

NCT02164084
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 2 Interventional Results available

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

NCT03599193
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Lotion, 0.1%, Tazarotene Cream, 0.1%
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Nov 2, 2026, 7:42 AM EST
Recruiting Phase 3 Interventional

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

NCT07863193
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Denifanstat, Placebo
Drug · Other
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
12 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Bryant, Arkansas • Fremont, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 3 Interventional Results available

Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

NCT02932267
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene 0.3% / BPO 2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 3 Interventional Results available

A Study of S6G5T-3 in the Treatment of Acne Vulgaris

NCT03761784
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Nov 2, 2026, 7:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing OTC Acne Treatment to Prescription Regimen

NCT01237821
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BenzaClin, Effaclar
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 1 Interventional

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

NCT01019603
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene, Tazaroc Gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Nov 2, 2026, 7:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus

NCT04993066
View directory record Official record
Conditions
Pseudofolliculitis Barbae, Unwanted Hair, Pigmented Lesions, Vascular Lesion, Onychomycosis, Wrinkle, Acne
Interventions
GentleMax Pro Plus
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of an Herbal-Based De-Pigmenting System

NCT02138539
View directory record Official record
Conditions
Melasma, Hyperpigmentation
Interventions
Herbal depigmenting agent (Epionce), Hydroquinone
Other · Drug
Lead sponsor
Sadick Research Group
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Nov 2, 2026, 7:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a Novel Skincare Regimen

NCT05517720
View directory record Official record
Conditions
Wrinkle, Photoaging, Acne, Skin Inflammation
Interventions
Aria Trio complete Facial System
Other
Lead sponsor
Trophy Skin
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo

NCT01243450
View directory record Official record
Conditions
Acne
Interventions
Tretinoin, placebo
Drug
Lead sponsor
Spear Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
958 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mountain Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 2 Interventional Results available

A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

NCT01631474
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01, Vehicle
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Sanford, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Nov 2, 2026, 7:42 AM EST
Active, not recruiting Early Phase 1 Interventional

Experience With Topical Acne Treatment

NCT05582434
View directory record Official record
Conditions
Acne
Interventions
clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel, adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel, Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Nov 2, 2026, 7:42 AM EST
Not listed Phase 2 Interventional

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

NCT04759664
View directory record Official record
Conditions
EGFRI Induced Acneiform Lesions
Interventions
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Glendale, California • Santa Monica, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 4 Interventional Results available

Effect of Samples on Acne Treatment With Epiduo® Gel

NCT01504204
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene + benzoyl peroxide samples, Adapalene + benzoyl peroxide from standard tube
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Nov 2, 2026, 7:42 AM EST
Completed Phase 3 Interventional

NATIENS: Optimal Management and Mechanisms of SJS/TEN

NCT02987257
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 2, 2026, 7:42 AM EST